Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer: A Window of Opportunity
Identifiers
Identifiers
URI: http://hdl.handle.net/20.500.11940/18489
PMID: 34834544
DOI: 10.3390/jpm11111190
ISSN: 2075-4426
Date issued
2021Journal title
JOURNAL OF PERSONALIZED MEDICINE
Type of content
Journal Article
Abstract
The treatment for nonmetastatic castration-resistant prostate cancer (nmCRPC) is a highly unmet medical need. The classic treatment approach for these patients-androgen deprivation therapy (ADT) alone-until metastatic progression is now considered suboptimal. Several randomized phase III clinical trials have demonstrated significant clinical benefits-including significantly better overall survival (OS)-for treatments that combine ADT with apalutamide, enzalutamide, and darolutamide. As a result, these approaches are now included in treatment guidelines and are considered a standard of care. In the present article, we discuss the changing landscape of the management of patients with nmCRPC.